日本 ,安斯泰来,Astellas,   
安斯泰来制药集团是一家总部位于日本东京的研发型制药企业，在全球范围内研发、生产、销售创新型医药产品。我们的使命是不断提升企业价值，致力于通过创新可靠的医药产品为全世界人民的健康做贡献实现我们的存在意义。

　　安斯泰来已经在需要高度专业技能的器官移植领域和泌尿领域成为全球专业治疗领域领导者。借助独特的产品线，我们逐步在其他目标领域培养支柱产品。在抗肿瘤领域，我们拥有了先进的抗体药物研究技术。同时强大的现金流确保我们能够持续投资于未来的成长。

　　在2007财务年度 (2007 年 4 月至 2008 年 3 月) 全球净销售额达 9,726 亿日元（97 亿美元）。安斯泰来已经成为日本第二大处方药品公司，全世界排名 20位的制药企业。目前全球员工约 14000 人。


为方便广大患者、医师及合作伙伴与安斯泰来制药（中国）有限公司的积极联络与沟通，及时处理来自各方的咨询反馈， 安斯泰来中国于即日正式启用400客户咨询专线：4000-8567-99，欢迎使用！

专线服务对象：患者、医院、药房、药品经营公司等。
服务范围：处理与安斯泰来中国上市产品有关的用药咨询、药品不良反应报告、药品真伪辨别咨询、购药咨询、质量投诉等。
工作时间：9:00-17:30（周一至周五），非工作时间可根据语音提示留言，我们会尽快与您联络！

 Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha?, TYO: 4503) is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha?) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha?).

Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

The company's headquarters are in Tokyo, with research centres in Tsukuba and Osaka. Clinical development is centred in Deerfield, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people.

Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943.

Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942.

Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards. Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D centre in Deerfield, Illinois. Yamanouchi's R&D centre in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991.

Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April 2005.

[edit] Products
Some of the key products produced by Astellas include:

Prograf (tacrolimus) - Prevention of post-transplant organ rejection
Protopic (tacrolimus ointment) - Atopic dermatitis (eczema)
Amevive (alefacept) - Plaque psoriasis
VESIcare (solifenacin succinate) - Overactive bladder (OAB)
Flomax (tamsulosin hydrochloride) - Benign prostatic hyperplasia (BPH)
Adenocard (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
Adenoscan (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
Lexiscan (regadenoson injection) - Pharmacologic stress agent for myocardial perfusion scan
Vaprisol (conivaptan) - Hyponatremia
AmBisome (amphotericin B) - Anti-fungal
Mycamine (micafungin sodium) - Anti-fungal
Vibativ (telavancin) - Antibiotic